Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
89Zr-anti-CD79b
- Development stage
- Preclinical
- Lead developer
- Washington University in St. Louis
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
89Zr-anti-CD79b is a zirconium-89 (89Zr)-labeled monoclonal antibody targeting CD79b, developed as an immuno-positron emission tomography (immunoPET) imaging agent. It consists of a human anti-human CD79b IgG1κ monoclonal antibody (sharing the same variable sequence as polatuzumab) conjugated to the chelator deferoxamine (DFO) and radiolabeled with the positron emitter zirconium-89. CD79b is a transmembrane protein that forms part of the B-cell receptor complex and is highly expressed and rapidly internalized in various B-cell lymphomas. 89Zr-anti-CD79b is designed for non-invasive PET imaging to diagnose, stratify, and assess treatment response in CD79b-expressing lymphomas, particularly in cases where CD20 epitopes are blocked or co-expression is variable.
- Other names
- 89Zr-DFO-anti-CD79banti-CD79b-Dfo-89Zranti-CD-79b-Dfo-89Zranti-CD 79b-Dfo-89Zr
02
Targets
B-cell antigen receptor complex-associated protein beta chain
Beyond the preview
Go deeper on 89Zr-anti-CD79b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 89Zr-anti-CD79b.